The Founders Just Bought $7 MILLION of Their Own Stock… What Do They Know?

Overview

The video argues that Helis Pharma (HELP) may have strong, underappreciated drug trial prospects, supported by unusual founder behavior and improving industry momentum.

Key Claims

1) Founder insider buying as a signal

Between Aug 31 and Sept 8, Helis founders Eric So and Paul Glavin reportedly bought about $7 million of stock via open-market purchases (not options or grants).

The narrator emphasizes this is notable because HELP is not “cheap”—it is up nearly 300% in three months—and the buying reportedly occurs right before a major upcoming catalyst.

2) A big imminent catalyst (Phase 3 timeline)

The video frames Helis’s largest near-term event as occurring in ~8 weeks, linked to topline results for its key Phase 3 trial, expected in Q4. One analyst cited in the video suggests a timing around mid-November.

The narrator claims the founder purchases happen about two months ahead of the readout.

3) Drug focus and potential differentiator

Helis is described as a clinical-stage biotech with no marketed products. Its lead candidate, HLP00003, is presented as an oral, adjunct therapy for major depressive disorder—taken in two doses 3 weeks apart.

The goal is to activate serotonin pathways related to neuroplasticity, potentially producing effects that last months after dosing. The FDA is said to have granted Breakthrough Therapy designation.

4) Industry backdrop improving

The narrator points to positive signals in related psychiatry/serotonin approaches, including:

• Definium Therapeutics reporting successful Phase 3 results for a similar serotonin-depression strategy.
• Eli Lilly reportedly agreeing to acquire Atai Beckley for $2.8B upfront, plus up to $3.8B in milestones—framed as evidence of Big Pharma interest and higher confidence in this psychiatric strategy area.

5) Price target and upside case

A referenced TD Cowan analyst allegedly increased the HELP price target from $8 to $62 (dated Aug 20).

The narrator highlights the valuation gap (HELP trading around 13 in the video) and argues that if Phase 3 resembles Phase 2 performance, the stock could re-rate sharply and become an acquisition target.

6) “Unheard of” Phase 2 claims, with caution

A physician subscriber named Carol argues the mechanism and clinical story are compelling, including a theory that neural pathway rewiring could be longer-lasting (possibly “permanent”), though the company is not said to claim that explicitly.

Carol also cautions that Phase 2 response/remission figures are based on very small patient numbers—the video cites 7 patients for the key figures—which is why Phase 3 matters.

7) Adjunct wording as a potential access advantage

A major analytical point is Helis positioning the therapy as an add-on (“adjunct”) rather than strictly treatment-resistant depression.

The video argues this could reduce barriers such as:

• extra failed-drug requirements, and/or
• insurance prior authorizations

…potentially enabling faster adoption and broader patient reach.

8) Additional pipeline note

The video briefly mentions a second program targeting generalized anxiety disorder, described as potentially large-market, especially given challenges and safety concerns around current benzodiazepine use.

9) Risk acknowledgment

Despite the bullish framing, the narrator repeatedly calls Helis speculative:

• no revenue,
• one main trial driving much of the value, and
• the stock already rising substantially.

Founder buying is presented as the reason to watch the setup despite uncertainty.

Presenters / Contributors Mentioned

• Video narrator/speaker (unnamed in the subtitles)
• Eric So — Helis Pharma founder/executive
• Paul Glavin — Helis Pharma founder/chief growth officer
• Carol — subscriber and physician who emailed insights
• TD Cowan analyst — mentioned regarding the price target change (name not given)
• Definium Therapeutics — mentioned for Phase 3 results
• Eli Lilly — mentioned as an acquirer